CEACAM6/CD66c Antibody (439424) [Alexa Fluor™ Plus 405]

• Reactivity: Hu
• Clone: 439424
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Alexa Fluor Plus 405

CEACAM6/CD66c Antibody (439424) [Alexa Fluor™ Plus 405] Summary

• Specificity: Detects human CEACAM-6/CD66c in direct ELISAs and Western blots. In direct ELISAs and Western blots, no cross-reactivity with recombinant human CEACAM-1, -3, or -5 is observed.
• Isotype: IgG2a
• Clonality: Monoclonal
• Host: Mouse

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for CEACAM6/CD66c Antibody (439424) [Alexa Fluor™ Plus 405]

• carcinoembryonic antigen-related cell adhesion molecule 6 (non-specific crossreacting antigen)
• carcinoembryonic antigen-related cell adhesion molecule 6
• CD66c antigen
• CD66c
• CEACAM6
• CEACAM-6
• CEAL
• NCA
• NCACEAL
• Non-specific crossreacting antigen
• Normal cross-reacting antigen

Background

Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM-6), previously called nonspecific cross‑reacting antigen (NCA) or CD66c, is one of seven human CEACAM family members within the immunoglobulin superfamily (1-4). In humans, CEACAMs include type I transmembrane proteins (CEACAM-1, -3, and -4) and Glycosylphosphatidylinositol (GPI)-linked molecules (CEACAM-5 through -8) (1). There is no human CEACAM-2. Human CEACAM-6 is a 90 kDa, GPI-linked membrane protein that contains a 34 amino acid (aa) signal sequence, a 286 aa extracellular domain (ECD), and a 24 aa hydrophobic C-terminal propeptide. The GPI membrane anchor is attached at the C-terminus following cleavage of the propeptide. CEACAM-6 contains one N-terminal V-type Ig-like domain (N domain), followed by two C2-type Ig-like domains (2-4). It shows considerable glycosylation, including (sialyl) Lewis^X, which mediates binding to E-Selectin, Galectins and some bacterial fimbrae (1, 2). Mature human CEACAM-6 shows 84%, 85%, 80%, 87% and 51% aa identity to the equivalent extracellular regions of human CEACAMs -1, -5 (CEA) and -8, rhesus CEACAM-2, and bovine CEACAM-6, respectively. CEACAM-6 is expressed by granulocytes and their precursors. Activation enhances surface expression by mobilizing CEACAM-6 from storage in azurophilic granules (5, 6). It often shows aberrant expression in acute lymphocytic leukemias (10). CEACAM-6 is also expressed in epithelia of various organs and is upregulated in pancreatic and colon adenocarcinomas and hyperplastic polyps (7, 8). Over-expression confers resistance to adhesion-related apoptosis (anoikis) in tumor cells (8, 9). CEACAM-6 is an intercellular adhesion molecule, forming both homotypic, and heterotypic bonds with CEACAM-1, -5 and -8 through interaction of the V-type Ig-like domains (11, 12). Cross-linking of neutrophil CEACAM-6 augments Integrin alpha _v beta ₃ and beta ₂-mediated adhesion, apparently by Src and Caveolin-mediated inside-out Integrin activation (8, 13, 14).

1. Beauchemin, N. et al. (1999) Exp. Cell Res. 252:243.
2. Skubitz, K.M. et al. (1999) J. Biol. Regul. Homeost. Agents 13:244.
3. Barnett, T. et al. (1988) Genomics 3:59.
4. Tawaragi, Y. et al. (1988) Biochem. Biophys. Res. Comm. 150:89.
5. Kuroki, M. et al. (1995) Immunol. Invest. 24:829.
6. Ducker, T.P. and K.M. Skubitz (1992) J. Leukoc. Biol. 52:11.
7. Scholzel, S. et al. (2000) Am. J. Pathol. 156:595.
8. Duxbury, M.S. et al. (2004) J. Biol. Chem. 279:23176.
9. Ilantzis, C. et al. (2002) Neoplasia 4:151.
10. Kalina, T. et al. (2005) BMC Cancer 5:38.
11. Oikawa, S. et al. (1992) Biochem. Biophys. Res. Commun. 186:881.
12. Kuroki, M. et al. (2001) J. Leukoc. Biol. 70:543.
13. Duxbury, M.S. et al. (2004) Biochem. Biophys. Res. Comm. 317:133.
14. Skubitz, K.M. et al. (1999) J. Leukoc. Biol. 60:106.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.